Table 3. TERT promoter mutations detected in both tumor and urine samples from RPC patients.

Case number	Sex M / F	Age at diagnosis (year)	Tumor size(CM)	TNM stage	TERT promoter mutation
					Tissue	Preoperative urine		Postoperative urine
					Sanger		castPCR	Sanger	castPCR
RPC-1	F	68	3.5	T1N0M0	wt	wt	wt	wt	wt
RPC-2	F	66	3	T1N0M0	wt	wt	wt	NA	NA
RPC-3	F	61	10	T1N0M0	wt	wt	wt	NA	NA
RPC-4	M	71	8	T3N0M0	C228T	C228T	C228T	NA	NA
RPC-5	M	43	5.5	T3N0M0	C228T	wt	C228T	NA	NA
RPC-6	M	65	1.8	T1N0M0	wt	wt	wt	wt	wt
RPC-7	F	82	6	T2N0M0	C228T	C228T	C228T	wt	wt
RPC-8	M	79	1	T1N0M0	wt	wt	C228T	NA	NA
RPC-9	M	71	3.5	T3N0M0	C228T	wt	C228T	NA	NA
RPC-10	M	63	5	T4N0M0	C228T	C228T	C228T	wt	wt
RPC-11	M	64	2.5	T3N0M0	C228T	C228T	C228T	NA	NA
RPC-12	M	64	3	T2N0M0	C228T	wt	wt	NA	NA
RPC-13	F	67	3.2	T1N0M0	C228T	wt	C228T	NA	NA
RPC-14	M	80	4.8	T3N0M0	wt	wt	wt	NA	NA
RPC-15	F	73	4.5	T2N0M0	wt	wt	wt	NA	NA
RPC-16	M	57	2	T3N0M0	wt	C228T	C228T	NA	NA

RPC, Renal pelvic carcinoma; M, Male; F, Female; castPCR, Competitive Allele-specific TaqMan PCR; NA, Not available; wt, Wild type; Sanger, Sanger sequencing